The structure of forest fund of DP «Prybuz'ke LG»

У статті проаналізовано сучасну структуру лісового фонду державного підприємства «Прибузьке лісове господарство» (далі – ДП «Прибузьке ЛГ») в якості індикатора видів лісокористування та збереженості природних екосистем Волинського Полісся. Для цього детально проаналізовано структуру лісового фонду підприємства за категоріями захисності (експлуатаційні, захисні, рекреаційно-оздоровчі ліси та ліси природоохоронного, наукового, історико-культурного призначення) та за категоріями земель (вкриті лісовою рослинністю, не вкриті лісовою рослинністю, нелісові землі, серед яких виділяють сільськогосподарські угіддя, води, болота, садиби й споруди, траси, піски й інші нелісові землі). Окремо проаналізовано структуру експлуатаційних, захисних, рекреаційно-оздоровчих та природоохоронних лісів за категоріями земель. Оскільки територія досліджуваного лісгоспу входить до двох адміністративних одиниць, проаналізовано структури лісового фонду ДП «Прибузьке ЛГ» межах Любомльського й Шацького районів. Дослідження побудовано на матеріалах ДП «Прибузьке ЛГ» та Волинського обласного управління лісового та мисливського господарства (далі ВОУЛМГ).The article contains analysis of the current structure of the forest state enterprise «Prybuz'ke forestry» (hereinafter − DP «Prybuz'ke LG») as one of the indicators of kinds of forest management and preservation of natural ecosystems of Volyn Polissya. With a purpose to do this, a detailed analysis of the structure of forest enterprises by categories of protection (operational, safety, recreational forests and forest conservation, scientific, historical and cultural) and by categories of land (covered with forest vegetation, not covered with forests, non-forest land, including isolated farmland, water, wetlands, farms and facilities, roads, sand and other non-forest land) were made. A separate analysis of the structure of operation, security, recreation and health improvement and conservation of forest according to the land categories was made. Since the studied forestry area is a part of two administrative units, the structure of forest state enterprise «Prybuz'ke LG» within Liuboml and Shatsk districts was analyzed. The study is based on the material of DP «Prybuz'ke LG» and Volyn Regional Office of a Forestry and Hunting (VROFH)

The Modern Structure of Land Use in Volyn Region

Відображено результати дослідження структури земельного фонду й особливостей землекористування у Волинській області та в розрізі її адміністративних районів станом на 01.01.2016 р. Розраховано коефіцієнти розораності території та сільськогосподарських угідь, рівень сільськогосподарської освоєності, частку лісовкритих площ, співвідношення природних і господарських угідь. При цьому показники міст обласного підпорядкування враховувалися до відповідних показників тих адміністративних районів, в межах яких вони знаходяться.The results of the investigation of the land fund structure and the features of land use in Volyn region in the context of its administrative districts on 01.01.2016 are presented. The coefficients of the cultivating territory and agricultural lands, the level of agricultural development, the share of forest cover areas, the ratio of natural and economic lands are calculated. At the same time the indicators of the cities of regional subordination were taken into account according to the administrative districts within which they are located

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

BACKGROUND Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361

Analysis and cartographic modeling of the structure of the land fund in Horokhiv district of Volyn region

У статті відображено результати дослідження структури земельного фонду та особливостей землекористування в Горохівському районі Волинської області в розрізі його адміністративних одиниць.The article deals with the results of the investigation of the land fund structure and features of land use in the Horokhiv district of the Volyn region in the conext of its administrative units

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)